Literature DB >> 28750838

Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis.

Brisas M Flores1, Anthony O'Connor2, Alan C Moss1.   

Abstract

BACKGROUND AND AIMS: Long-standing ulcerative colitis is an established risk factor for colorectal neoplasia. A number of observational studies have suggested that evidence of mucosal inflammation (endoscopic or histologic) is associated with a greater risk for colorectal neoplasia than is mucosal healing. Our goal was to systematically analyze the risk of colorectal neoplasia in patients with ulcerative colitis who have ongoing mucosal inflammation to better inform surveillance strategies.
METHODS: We performed a systematic review and meta-analysis of the effect of endoscopic and/or histologic inflammation on the risk of colorectal neoplasia in cohort and case-control studies. Sensitivity analyses for study setting and case definition were performed.
RESULTS: Six studies met the inclusion criteria, incorporating outcomes in 1443 patients. No study used a single validated measure for mucosal inflammation. The pooled odds ratio for colorectal neoplasia was 3.5 (95% confidence interval [CI], 2.6-4.8; P < .001) in those with any mucosal inflammation and 2.6 (95% CI, 1.5-4.5; P = .01) in those with histologic inflammation, when compared with those with mucosal healing. The overall quality of the studies was good.
CONCLUSION: The presence of objective evidence of mucosal inflammation during follow-up in patients with ulcerative colitis is associated with a greater risk of subsequent colorectal neoplasia than in those with mucosal healing. This risk factor should be considered in guidelines on surveillance intervals for these patients.
Copyright © 2017 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28750838     DOI: 10.1016/j.gie.2017.07.028

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  25 in total

1.  Endoscopic surveillance strategies for dysplasia in ulcerative colitis.

Authors:  Christine Verdon; Achuthan Aruljothy; Peter L Lakatos; Talat Bessissow
Journal:  Frontline Gastroenterol       Date:  2019-04-12

Review 2.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

3.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

Review 4.  Maneuvering Clinical Pathways for Ulcerative Colitis.

Authors:  Christopher M Johnson; Catherine D Linzay; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2019-09-05

Review 5.  Mucosal healing in inflammatory bowel disease: Expanding horizon.

Authors:  Jimil Shah; Manik Lal Thakur; Usha Dutta
Journal:  Indian J Gastroenterol       Date:  2019-04-29

6.  Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation.

Authors:  Orhan Sezgin; Burcu Boztepe; Enver Üçbilek; Engin Altintas; Havva Didem Celikcan
Journal:  Turk J Gastroenterol       Date:  2021-10       Impact factor: 1.852

7.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

Review 8.  Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.

Authors:  Aderson Omar Mourão Cintra Damião; Natália Sousa Freitas Queiroz
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

9.  Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis.

Authors:  Christoffer Soendergaard; Peter Helding Kvist; Peter Thygesen; Mats Reslow; Ole Haagen Nielsen; John Joseph Kopchick; Thomas Lindebo Holm
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

10.  Lactobacillus coryniformis MXJ32 administration ameliorates azoxymethane/dextran sulfate sodium-induced colitis-associated colorectal cancer via reshaping intestinal microenvironment and alleviating inflammatory response.

Authors:  Tao Wang; Leshan Zhang; Panpan Wang; Yilin Liu; Gangtu Wang; Yuanyuan Shan; Yanglei Yi; Yuan Zhou; Bianfang Liu; Xin Wang; Xin Lü
Journal:  Eur J Nutr       Date:  2021-06-29       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.